KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
BioAtla, Inc.
Blokhin's Russian Cancer Research Center
Al-Azhar University
Fox Chase Cancer Center
M.D. Anderson Cancer Center
Sichuan Cancer Hospital and Research Institute
University of Chicago
Eli Lilly and Company
GERCOR - Multidisciplinary Oncology Cooperative Group
University of Pittsburgh
University of Kansas Medical Center
University of Pittsburgh
Fox Chase Cancer Center
University Hospital, Ghent
Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
National University Hospital, Singapore
Austrian Breast & Colorectal Cancer Study Group
Eli Lilly and Company
Eli Lilly and Company